There are 2789 resources available
1291P - A phase II study of nivolumab rechallenge therapy in advanced NSCLC patients who responded to prior anti-PD-1/L1 inhibitors: West Japan Oncology Group 9616L
Presenter: Shunsuke Teraoka
Session: ePoster Display
1292P - Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703)
Presenter: Ryo Toyozawa
Session: ePoster Display
1294P - 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC
Presenter: Filippo Dall'Olio
Session: ePoster Display
1295P - Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone
Presenter: Mathilde Bureau
Session: ePoster Display
1296P - Immune checkpoint inhibitors with or without bone targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio
Presenter: Alberto Bongiovanni
Session: ePoster Display
1298P - PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy
Presenter: Sally Lau
Session: ePoster Display
1299P - Effect of fat tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Presenter: Konstantinos Rounis
Session: ePoster Display